MedPath

PREECLAMPSIA FOUNDATION

🇺🇸United States
Ownership
-
Established
2000-01-01
Employees
-
Market Cap
-
Website
http://www.preeclampsia.org/

Clinical Trials

1

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

The Preeclampsia Registry

Recruiting
Conditions
Preeclampsia
Eclampsia
HELLP Syndrome
Toxemia
Hypertensive Disorder of Pregnancy
First Posted Date
2024-04-22
Last Posted Date
2024-04-22
Lead Sponsor
Preeclampsia Foundation
Target Recruit Count
20000
Registration Number
NCT06377878
Locations
🇺🇸

Preeclampsia Foundation, Melbourne, Florida, United States

News

Mirvie's RNA Blood Test Predicts Preeclampsia Risk Months Before Symptoms in Major Study

Mirvie's blood test successfully identified 91% of preterm preeclampsia cases in women over 35 without pre-existing conditions, using RNA signatures detectable at 17.5-22 weeks gestation.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.